WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Author: search.filters.author.Ozdemir, Nuriye

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study
    (TAYLOR \& FRANCIS LTD, 2022-01-01) Basoglu, Tugba; Sakin, Abdullah; Erol, Cihan; Ozden, Ercan; cabuk, Devrim; Cilbir, Ebru; Tataroglu ozyukseler, Deniz; Ayhan, Murat; Sendur, Mehmet Ali; Dogan, Mutlu; Oksuzoglu, Berna; Eryilmaz, Melek Karakurt; Er, Ozlem; Tasci, Elif Senocak; Ozyurt, Neslihan; Dulgar, Ozgecan; Ozen, Mirac; Hacibekiroglu, Ilhan; Oner, Irem; Bekmez, Esma Turkmen; Cagri Yildirim, Hasan; Yalcin, Suayib; Paydas, Semra; Yekeduz, Emre; Aksoy, Asude; Ozcelik, Melike; Oyman, Abdilkerim; Almuradova, Elvina; Karabulut, Bulent; Demir, Nazan; Dincer, Murat; Ozdemir, Nuriye; Erdem, Dilek; Ak, Naziye; Inal, Ali; Salim, Derya Kivrak; Deniz, Gulhan Ipek; Sakalar, Teoman; Gulmez, Ahmet; Kacan, Turgut; Ozdemir, Ozlem; Alan, Ozkan; Unal, Caglar; Karakas, Yusuf; Turhal, Serdar; Yumuk, Perran Fulden
    Neoadjuvant chemotherapy (NACT) in gastroesophageal junction (GEJ) and gastric cancer (GC) was shown to improve survival in recent studies. We aimed to share our real-life experience of patients who received NACT to compare the efficacy and toxicity profile of different chemotherapy regimens in our country. This retrospective multicentre study included locally advanced GC and GEJ cancer patients who received NACT between 2007 and 2021. Relation between CT regimens and pathological evaluation were analysed. A total of 794 patients from 45 oncology centers in Turkey were included. Median age at the time of diagnosis was 60 (range: 18-86). Most frequent NACT regimens used were FLOT (65.4\%), DCF (17.4\%) and ECF (8.1\%), respectively. In the total study group, pathological complete remission (pCR) rate was 7.2\%, R0 resection rate 86.4\%, and D2 dissection rate was 66.8\%. Rate of pCR and near-CR (24\%), and R0 resection (84\%) were numerically higher in FLOT arm (p > 0.05). Patients who received FLOT had also higher chemotherapy-related toxicity rate compared to patients who received other regimens (p > 0.05). Median follow-up time was 16 months (range: 1-154 months). Estimated median overall survival (OS) was 58.4months (95\% CI: 35.2-85.7) and disease-free survival (DFS) was 50.7 months (95\% CI: 25.4-75.9). The highest 3-year estimated OS rate was also shown in FLOT arm (68\%). We still do not know which NACT regimen is the best choice for daily practice. Clinicians should tailor treatment regimens according to patients' multifactorial status and comorbidities for to obtain best outcomes. Longer follow-up period needs to validate our results.
  • No Thumbnail Available
    Item
    Flare Phenomenon in Advanced Colorectal Cancer: Cessation of evacizumab after Predefined Cycles of Therapy may not Affect Outcome
    (AKAD DOKTORLAR YAYINEVI, 2017-01-01) Besen, A. Ali; Kose, Fatih; Sumbul, Ahmet T.; Ozdemir, Nuriye; Ozyilkan, Ozgur; Zengin, Nurullah; Abali, Huseyin
    Limited number of experimental and clinical studies showed rapid tumor regrowth after bevacizumab cessation in advanced colorectal cancer. We retrospectively evaluated rapid regrowth phenomenon in 105 patients those who were treated with the predefined number of chemotherapy cycles and grouped according to whether the chemotherapy regimen in the first line setting included bevacizumab (CT-Bev arm) or not (CT arm). Median age was 55 years old. Median overall and progression free survival times were 27 and 11 months, respectively. Rapid progression rates were 42\% and 40\% in CT arm and CT -Bev arm without no statistically significant difference (p= 0.84). In CT arm, significantly more patients with stable disease (SD) progressed rapidly compared to patients with complete (CR) or partial response (PR) (53\% vs. 27\%, p= 0.04). This result was also similar in CT-Bev arm (48\% vs. 30\%, p= 0.27) but could not reach to the significant p-value. Overall survival 2, the time from the end of last dose of chemotherapy +/- bevacizumab to death, was significantly shorter in both CT and CT -Bev arms for patients who showed SD compared to CR or PR (15 vs 38 months) (p< 0.001).Current study supports that withdrawal of bevacizumab after predefined treatment cycles may not have any adverse effect on patients' outcome of advanced CRC. This result is particularly acceptable for the patients who show CR or PR to the treatment.